FRONTLINE THERAPY OF CHRONIC MYELOID LEUKEMIA (CML)

被引：0
|
作者：
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷
关键词：
D O I：
10.1016/S0145-2126(14)70007-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-001
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [1] The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)
    Wolfe, Heather R.
    Rein, Lindsay A. M.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (05) : 448 - 454
  • [2] The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)
    Heather R. Wolfe
    Lindsay A. M. Rein
    Current Hematologic Malignancy Reports, 2021, 16 : 448 - 454
  • [3] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Jabbour, Elias
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [4] Debating Frontline Therapy in Chronic Myeloid Leukemia
    Bi, Xia
    Ramanathan, Sabarina
    Keiffer, Gina
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [6] Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction
    Tong, Weigang
    Kantarjian, Hagop
    O'Brien, Susan
    Faderl, Stefan
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Burton, Elizabeth
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 741 - 741
  • [7] Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
    Boddu, Prajwal
    Jain, Preetesh
    Borthakur, Gautam
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Daver, Naval
    Kadia, Tapan
    Ravandi, Farhad
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3172 - 3180
  • [8] Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
    Haddad, Fadi G.
    Sasaki, Koji
    Nasr, Lewis
    Short, Nicholas J.
    Kadia, Tapan
    Dellasala, Sara
    Cortes, Jorge
    Nicolini, Franck E.
    Issa, Ghayas C.
    Jabbour, Elias
    Kantarjian, Hagop
    CANCER, 2024, 130 (19) : 3344 - 3352
  • [9] Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Daver, Naval G.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Skinner, Jeff
    Konopleva, Marina
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [10] Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia
    Marin, David
    SEMINARS IN HEMATOLOGY, 2010, 47 (04) : 312 - 318
12345